HomeCompareCWBR vs QYLD

CWBR vs QYLD: Dividend Comparison 2026

CWBR yields 487.80% · QYLD yields 11.92%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CWBR wins by $50753.87M in total portfolio value
10 years
CWBR
CWBR
● Live price
487.80%
Share price
$0.41
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$50753.89M
Annual income
$36,168,404,531.85
Full CWBR calculator →
QYLD
Global X Nasdaq 100 Covered Call ETF
● Live price
11.92%
Share price
$17.15
Annual div
$2.04
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$25.4K
Annual income
$5,659.31
Full QYLD calculator →

Portfolio growth — CWBR vs QYLD

📍 CWBR pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCWBRQYLD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CWBR + QYLD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CWBR pays
QYLD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CWBR
Annual income on $10K today (after 15% tax)
$41,463.41/yr
After 10yr DRIP, annual income (after tax)
$30,743,143,852.07/yr
QYLD
Annual income on $10K today (after 15% tax)
$1,013.51/yr
After 10yr DRIP, annual income (after tax)
$4,810.41/yr
At 15% tax rate, CWBR beats the other by $30,743,139,041.66/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CWBR + QYLD for your $10,000?

CWBR: 50%QYLD: 50%
100% QYLD50/50100% CWBR
Portfolio after 10yr
$25376.96M
Annual income
$18,084,205,095.59/yr
Blended yield
71.26%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on CWBR right now

CWBR
Analyst Ratings
5
Buy
Consensus: Buy
Altman Z
-13.8
Piotroski
1/9
QYLD
No analyst data
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CWBR buys
0
QYLD buys
0
No recent congressional trades found for CWBR or QYLD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCWBRQYLD
Forward yield487.80%11.92%
Annual dividend / share$2.00$2.04
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$50753.89M$25.4K
Annual income after 10y$36,168,404,531.85$5,659.31
Total dividends collected$49478.61M$27.1K
Payment frequencyquarterlymonthly
SectorStockETF

Year-by-year: CWBR vs QYLD ($10,000, DRIP)

YearCWBR PortfolioCWBR Income/yrQYLD PortfolioQYLD Income/yrGap
1← crossover$59,480$48,780.49$10,352$1,192.36+$49.1KCWBR
2$334,811$271,167.03$10,830$1,347.57+$324.0KCWBR
3$1,784,770$1,426,522.08$11,460$1,539.07+$1.77MCWBR
4$9,016,553$7,106,848.63$12,275$1,777.84+$9.00MCWBR
5$43,202,271$33,554,559.81$13,323$2,078.95+$43.19MCWBR
6$196,483,123$150,256,693.49$14,667$2,463.34+$196.47MCWBR
7$848,895,486$638,658,543.63$16,396$2,960.57+$848.88MCWBR
8$3,487,095,949$2,578,777,778.75$18,631$3,612.97+$3487.08MCWBR
9$13,631,297,985$9,900,105,319.66$21,548$4,482.15+$13631.28MCWBR
10$50,753,893,375$36,168,404,531.85$25,398$5,659.31+$50753.87MCWBR

CWBR vs QYLD: Complete Analysis 2026

CWBRStock

CohBar, Inc., a clinical stage biotechnology company, focuses in the research and development of mitochondria based therapeutics (MBTs) for the treatment of chronic and age-related diseases. The company develops MBTs to treat non-alcoholic steatohepatitis (NASH), obesity, fatty liver disease, idiopathic pulmonary fibrosis, type 2 diabetes, acute respiratory distress syndrome, cancer, and cardiovascular diseases, such as Alzheimer's disease. Its lead clinical candidate is CB4211, a novel refined analog of the MOTS-c mitochondrial derived peptide, which is in Phase Ib stage of a Phase Ia/Ib clinical trial for the treatment of NASH and obesity. The company's preclinical programs include CB5138 analogs for fibrotic diseases; and CB5064 analogs for COVID-19 associated ARDS. CohBar, Inc. was incorporated in 2007 and is headquartered in Menlo Park, California.

Full CWBR Calculator →

QYLDETF

The Global X Nasdaq 100 Covered Call ETF (QYLD) seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the Cboe Nasdaq-100 BuyWrite V2 Index.

Full QYLD Calculator →
📬

Get this CWBR vs QYLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CWBR vs SCHDCWBR vs JEPICWBR vs OCWBR vs KOCWBR vs MAINCWBR vs XYLDCWBR vs JEPQCWBR vs RYLD

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.